SCHEMBL6722740

SCHEMBL6722740

NS(=O)(=O)c1ccc(-c2ncccc2-c2cccc(Cl)c2)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
FEN1 P39748 5/20 0.42
ALOX5AP P20292 4/20 0.42
RORB Q92753 1/20 0.41
KMO O15229 1/20 0.41
PTGS1 P23219 3/20 0.41
PTGS2 P35354 3/20 0.41
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
SLC40A1 Q9NP59 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
KCNN4 O15554 1/20 0.39
KCNA5 P22460 1/20 0.39
GLO1 Q04760 1/20 0.39
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722662 0.91 CA1 (0.41) NPC1HPGDHTTFEN1ALOX5AP
SCHEMBL6723055 0.89 PTGS2 (0.43) FEN1ALOX5APKMOPTGS1PTGS2
SCHEMBL6728769 0.89 FEN1 (0.46) FEN1ALOX5APKMOPTGS1PTGS2
SCHEMBL7548196 0.88 PTGS2 (0.47) FEN1ALOX5APRORBKMOPTGS1
SCHEMBL7543924 0.88 PTGS2 (0.47) FEN1ALOX5APRORBKMOPTGS1
SCHEMBL6718427 0.88 FEN1 (0.46) FEN1ALOX5APPTGS1PTGS2CA1
SCHEMBL6723777 0.87 KMO (0.46) FEN1ALOX5APKMOPTGS1PTGS2
SCHEMBL6718496 0.87 PTGS2 (0.52) FEN1ALOX5APPTGS1PTGS2CA1
SCHEMBL6730177 0.86 FEN1 (0.42) FEN1ALOX5APKMOPTGS1PTGS2
SCHEMBL6722065 0.86 PTGS2 (0.43) FEN1ALOX5APKMOPTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 NPC1 3884/4885HPGD 1751/4885HTT 3966/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 NPC1 3792/4885HPGD 1474/4885HTT 3883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.